Cutaneous active vasodilation in humans is mediated by cholinergic nerve cotransmission. 1995

D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
Department of Medicine, University of Texas Health Science Center at San Antonio 78284, USA.

During heat stress, increases in blood flow in nonglabrous skin in humans are mediated through active vasodilation by an unknown neurotransmitter mechanism. To investigate this mechanism, a three-part study was performed to determine the following: (1) Is muscarinic receptor activation necessary for active cutaneous vasodilation? We iontophoretically applied atropine to a small area of forearm skin. At that site and an untreated control site, we measured the vasomotor (laser-Doppler blood flow [LDF]) and sudomotor (relative humidity) responses to whole-body heat stress. Blood pressure was monitored. Cutaneous vascular conductance (CVC) was calculated (LDF divided by mean arterial pressure). Sweating was blocked at treated sites only. CVC rose at both sites (P < .05 at each site); thus, cutaneous active vasodilation is not effected through muscarinic receptors. (2) Are nonmuscarinic cholinergic receptors present on cutaneous arterioles? Acetylcholine (ACh) was iontophoretically applied to forearm skin at sites pretreated by atropine iontophoresis and at untreated sites. ACh increased CVC at untreated sites (P < .05) but not at atropinized sites. Thus, the only functional cholinergic receptors on cutaneous vessels are muscarinic. (3) Does cutaneous active vasodilation involve cholinergic nerve cotransmission? Botulinum toxin was injected intradermally in the forearm to block release of ACh and any coreleased neurotransmitters. Heat stress was performed as in part 1 of the study. At treated sites, CVC and relative humidity remained at baseline levels during heat stress (P > .05). Active vasodilator and sudomotor responses to heat stress were abolished by botulinum toxin. We conclude that cholinergic nerve activation mediates cutaneous active vasodilation through release of an unknown cotransmitter, not through ACh.

UI MeSH Term Description Entries
D007478 Iontophoresis Therapeutic introduction of ions of soluble salts into tissues by means of electric current. In medical literature it is commonly used to indicate the process of increasing the penetration of drugs into surface tissues by the application of electric current. It has nothing to do with ION EXCHANGE; AIR IONIZATION nor PHONOPHORESIS, none of which requires current. Iontophoreses
D008297 Male Males
D009435 Synaptic Transmission The communication from a NEURON to a target (neuron, muscle, or secretory cell) across a SYNAPSE. In chemical synaptic transmission, the presynaptic neuron releases a NEUROTRANSMITTER that diffuses across the synaptic cleft and binds to specific synaptic receptors, activating them. The activated receptors modulate specific ion channels and/or second-messenger systems in the postsynaptic cell. In electrical synaptic transmission, electrical signals are communicated as an ionic current flow across ELECTRICAL SYNAPSES. Neural Transmission,Neurotransmission,Transmission, Neural,Transmission, Synaptic
D011950 Receptors, Cholinergic Cell surface proteins that bind acetylcholine with high affinity and trigger intracellular changes influencing the behavior of cells. Cholinergic receptors are divided into two major classes, muscarinic and nicotinic, based originally on their affinity for nicotine and muscarine. Each group is further subdivided based on pharmacology, location, mode of action, and/or molecular biology. ACh Receptor,Acetylcholine Receptor,Acetylcholine Receptors,Cholinergic Receptor,Cholinergic Receptors,Cholinoceptive Sites,Cholinoceptor,Cholinoceptors,Receptors, Acetylcholine,ACh Receptors,Receptors, ACh,Receptor, ACh,Receptor, Acetylcholine,Receptor, Cholinergic,Sites, Cholinoceptive
D011976 Receptors, Muscarinic One of the two major classes of cholinergic receptors. Muscarinic receptors were originally defined by their preference for MUSCARINE over NICOTINE. There are several subtypes (usually M1, M2, M3....) that are characterized by their cellular actions, pharmacology, and molecular biology. Muscarinic Acetylcholine Receptors,Muscarinic Receptors,Muscarinic Acetylcholine Receptor,Muscarinic Receptor,Acetylcholine Receptor, Muscarinic,Acetylcholine Receptors, Muscarinic,Receptor, Muscarinic,Receptor, Muscarinic Acetylcholine,Receptors, Muscarinic Acetylcholine
D001905 Botulinum Toxins Toxic proteins produced from the species CLOSTRIDIUM BOTULINUM. The toxins are synthesized as a single peptide chain which is processed into a mature protein consisting of a heavy chain and light chain joined via a disulfide bond. The botulinum toxin light chain is a zinc-dependent protease which is released from the heavy chain upon ENDOCYTOSIS into PRESYNAPTIC NERVE ENDINGS. Once inside the cell the botulinum toxin light chain cleaves specific SNARE proteins which are essential for secretion of ACETYLCHOLINE by SYNAPTIC VESICLES. This inhibition of acetylcholine release results in muscular PARALYSIS. Botulin,Botulinum Neurotoxin,Botulinum Neurotoxins,Clostridium botulinum Toxins,Botulinum Toxin,Neurotoxin, Botulinum,Neurotoxins, Botulinum,Toxin, Botulinum,Toxins, Botulinum,Toxins, Clostridium botulinum
D005260 Female Females
D006358 Hot Temperature Presence of warmth or heat or a temperature notably higher than an accustomed norm. Heat,Hot Temperatures,Temperature, Hot,Temperatures, Hot
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006813 Humidity A measure of the amount of WATER VAPOR in the air. Humidities

Related Publications

D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
April 2023, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
September 2006, American journal of physiology. Regulatory, integrative and comparative physiology,
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
September 2003, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
October 1991, The American journal of physiology,
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
March 2005, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
September 2007, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
September 1998, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
April 2001, Journal of applied physiology (Bethesda, Md. : 1985),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
December 1998, Hypertension (Dallas, Tex. : 1979),
D L Kellogg, and P E Pérgola, and K L Piest, and W A Kosiba, and C G Crandall, and M Grossmann, and J M Johnson
February 2002, Journal of applied physiology (Bethesda, Md. : 1985),
Copied contents to your clipboard!